| __timestamp | Neurocrine Biosciences, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 19928000 |
| Thursday, January 1, 2015 | 32480000 | 30842000 |
| Friday, January 1, 2016 | 68081000 | 46527000 |
| Sunday, January 1, 2017 | 169906000 | 34451000 |
| Monday, January 1, 2018 | 248932000 | 34409000 |
| Tuesday, January 1, 2019 | 354100000 | 34417000 |
| Wednesday, January 1, 2020 | 433300000 | 145290000 |
| Friday, January 1, 2021 | 583300000 | 298358000 |
| Saturday, January 1, 2022 | 752700000 | 488691000 |
| Sunday, January 1, 2023 | 887600000 | 468946000 |
| Monday, January 1, 2024 | 1007200000 |
Cracking the code
In the competitive world of biotechnology, managing expenses is crucial for success. Neurocrine Biosciences, Inc. and Novavax, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Novavax's expenses have grown by approximately 2,300%, indicating a more conservative approach.
By 2023, Neurocrine's SG&A expenses reached nearly double those of Novavax, highlighting its expansive operational scale. This divergence in financial strategy underscores the different paths these companies have taken in the biotech landscape. As the industry evolves, understanding these financial dynamics offers valuable insights into the strategic priorities of leading biotech firms.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and Novavax, Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: MorphoSys AG vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Novavax, Inc.